GlaxoSmithKline

The multiyear agreement will focus on speeding clinical trials and drug development in oncology and nonalcoholic steatohepatitis.

Also: Truepill launches a COVID-19 test coverage platform for insurers, and 23andMe extends its partnership with GSK.

The partnership expands on the companies’ earlier collaboration announced in late 2019.

Funds will be used to acquire more data sets and develop AI analysis.

MobiHealthNews tracked investments, pilots, partnerships and app launches from major pharma companies during the quarter.

23andMe on Wednesday announced that GlaxoSmithKline has invested $300 million to gain exclusive access to the genetic testing startup’s DNA database.

Earnings reports shared by neurostimulation and digital medicine company NeuroMetrix during a Q2 investors’ call showed a slight drop in total revenue as the company is preparing to place its marketing weight behind the launch of its updated wearable pain relief product, Quell.

According to a report in Bloomberg, GlaxoSmithKline is in talks with Qualcomm to create a new joint venture to develop medical technology.

GSK's Ellipta inhaler GlaxoSmithKline and Madison, Wisconsin-based Propeller Health announced a partnership today in which Propeller will develop and manufacture a custom sensor for GSK's Ellipta inhaler for COPD patients.

Over the last two years, big pharma has gotten behind the idea of smartphone-connected inhalers for asthma and COPD in a big way.